HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden

Abstract: The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with high tumor burden and prior tumor‐reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor‐derived HLA‐matched allogeneic CAR‐T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR‐T therapy.

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden ; day:27 ; month:03 ; year:2022 ; extent:6
ImmunoMedicine ; (27.03.2022) (gesamt 6)

Urheber
Huang, Yue
Yu, Qin
Yin, Elaine Tan Su
Wei, Guoqing
Wu, Wenjun
Chang, Alex H.
Huang, He
Hu, Yongxian

DOI
10.1002/imed.1032
URN
urn:nbn:de:101:1-2022032815081697677546
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:22 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.

Beteiligte

  • Huang, Yue
  • Yu, Qin
  • Yin, Elaine Tan Su
  • Wei, Guoqing
  • Wu, Wenjun
  • Chang, Alex H.
  • Huang, He
  • Hu, Yongxian

Ähnliche Objekte (12)